Latest News

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

CDC report: HCV persists despite decade-old cure due to payer barriers and screening failures.

HCV Medicaid Access dashboard 2023 update: progress in eliminating treatment restrictions by state.

2023 outlook: CVS PBM discrimination lawsuit, Medicaid enforcement, and state-sponsored discrimination threats.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

Supreme Court allows states to ration hepatitis C care in prisons, setting dangerous precedent for incarcerated people.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.

NASTAD's hepatitis C navigation toolkit uses peer navigators and wraparound services for people who use drugs.